Trial reportLasers in medical science2025
Impact of laser power settings on sexual and urinary outcomes in holmium laser enucleation of the prostate: a multicenter randomized controlled trial.
Trial report in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virtual basket mode in HoLEP: reduced early dysuria and faster continence recovery without loss of efficacy.The Canadian journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Holmium Laser Enucleation of the Prostate (HoLEP) has emerged as a definitive treatment for benign prostatic hyperplasia (BPH). However, the influence of laser power settings on postoperative sexual function and urinary outcomes remains controversial. This study aimed to compare high-power (HP) and low-power (LP) HoLEP in sexually active men with BPH, with a particular focus on erectile function preservation and alleviation of lower urinary tract symptoms (LUTS). In a multicenter, prospective, double-blind randomized controlled trial, 200 sexually active male patients with symptomatic BPH refractory to medical therapy were enrolled and randomly assigned to either HP-HoLEP or LP-HoLEP. Primary outcomes were assessed via changes in the International Index of Erectile Function (IIEF-5) and International Prostate Symptom Score (IPSS) at 1, 3, and 6 months postoperatively. Secondary endpoints included measurements of maximum urinary flow rate (Qmax), detailed operative parameters, and postoperative complications classified according to the Clavien-Dindo system. A total of 184 patients completed the study (HP group, n = 94; LP group, n = 90). Both groups exhibited significant postoperative improvements in LUTS and Qmax. A transient decline in IIEF-5 scores was observed at 1 month, with full recovery by the 3-month follow-up; no significant differences in erectile function were found between the groups at any time point. Notably, the LP group experienced longer enucleation and overall operation times but reported lower early postoperative pain scores. The complication profiles were similar between the two cohorts. Both HP-HoLEP and LP-HoLEP provide effective relief of BPH symptoms while maintaining long-term sexual function in sexually active men. The choice of laser power settings may be tailored according to patient characteristics and surgeon preference without compromising clinical outcomes. Future large-scale studies are recommended to validate these results across diverse clinical settings.Clinical Trial Registration Registration was completed on the China National Universal Health Insurance Information Platform under the identifier MR-32-20-004219.
Indexed as
Identifiers
40553165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.